Trial Profile
A Randomized Placebo-controlled Double Blind Trial of Liraglutide 3 mg [Saxenda] on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With Polycystic Ovary Syndrome (PCOS)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Jun 2022
Price :
$35
*
At a glance
- Drugs Liraglutide (Primary)
- Indications Obesity
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- Acronyms SAXAPCOS
- 13 Jun 2022 Primary endpoint has been met (Free Androgen Index (FAI)) , according to Results published in the Fertility and Sterility
- 13 Jun 2022 Primary endpoint has been met (Absolute Body Weight (BW)) , according to Results published in the Fertility and Sterility
- 13 Jun 2022 Results published in the Fertility and Sterility